Pharma Pulse 3/27/24: What's the ROI on GenAI? Virtual Second Opinions Save Over $8,700 Per Patient & more

Addressing Unmet Needs in Schizophrenia, Pulmonary Arterial Hypertension & NASH

In this Pharmaceutical Executive video interview, Optum Rx clinical pharmacist, Arash Sadeghi, discusses the three drugs featured in their Drug Pipeline Insights Report for 2024 and which unmet needs they address.

CMS Estimates Savings for Patients from Medicare Inflation Rebates

Medicare Part B beneficiaries may save between $1 and $3,575 per average dose for the 41 drugs whose prices have risen higher than inflation.

CFOs Tackle Thorny Calculus on Gen AI: What’s the Return on Investment?

Companies from Motorola Solutions to Intuit are leaning on their finance teams to weigh the possible benefits against the costs—and keep those costs in check.

Virtual Second Opinions Save Over $8,700 Per Patient, New Analysis Finds

Third-party research confirms significant impact of specialty expertise on patients’ quality of life and costs across the healthcare continuum

Simon-Kucher on LinkedIn:

In the second part of his interview with Pharmaceutical Commerce Magazine, our expert Joerg Tritschler discusses the current challenges facing emerging biopharma companies. He explores strategies for demonstrating the value of their early-stage drug candidates to potential investors or buyers. https://lnkd.in/eM3ZFXfv
#Pharma #Biopharma #Healthcare #SimonKucher

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs